These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 34631533)

  • 1. The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody
    Fujisaki T; Watanabe S; Ota T; Kushiro K; Sato Y; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Matsumoto N; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Hayashi M; Ohshima Y; Koya T; Kikuchi T
    Front Oncol; 2021; 11():704475. PubMed ID: 34631533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.
    Torasawa M; Yoshida T; Takeyasu Y; Shimoda Y; Tateishi A; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Takahashi K; Ohe Y
    Cancer Med; 2023 Jun; 12(11):12388-12401. PubMed ID: 37062059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
    Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors.
    Cook S; Samuel V; Meyers DE; Stukalin I; Litt I; Sangha R; Morris DG; Heng DYC; Pabani A; Dean M; Navani V
    JAMA Netw Open; 2024 Jan; 7(1):e2352302. PubMed ID: 38236598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis.
    Ngamphaiboon N; Ithimakin S; Siripoon T; Sintawichai N; Sriuranpong V
    BMC Cancer; 2021 Nov; 21(1):1275. PubMed ID: 34823493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
    Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
    Front Oncol; 2021; 11():749064. PubMed ID: 34900695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
    Guo M; VanderWalde AM; Yu X; Vidal GA; Tian GG
    Clin Lung Cancer; 2022 Dec; 23(8):686-693. PubMed ID: 36050243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events.
    Nizam A; Rader RK; Tzeng A; Wei W; Sheng IY; Martin A; Wee CE; Gilligan TD; Gupta S; Ornstein MC
    Clin Genitourin Cancer; 2024 Apr; 22(2):368-379. PubMed ID: 38245437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis.
    McKinley BJ; Pai TS; Wolf EB; Li S; Correia GSC; Zhao Y; Manochakian R; Lou Y
    Front Oncol; 2024; 14():1417175. PubMed ID: 38974234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
    Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
    Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subsequent systemic therapy for non-small cell lung cancer patients with immune checkpoint inhibitor-related interstitial lung disease.
    Sato Y; Watanabe S; Ota T; Kushiro K; Fujisaki T; Takahashi M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Hokari S; Kondo R; Hayashi M; Ishikawa H; Miyabayashi T; Abe T; Miura S; Tanaka H; Okajima M; Terada M; Ishida T; Iwashima A; Sato K; Yoshizawa H; Aoki N; Ohshima Y; Koya T; Kikuchi T
    Transl Lung Cancer Res; 2021 Jul; 10(7):3132-3143. PubMed ID: 34430353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.
    Zhou X; Yao Z; Yang H; Liang N; Zhang X; Zhang F
    BMC Med; 2020 Apr; 18(1):87. PubMed ID: 32306958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
    Ng KYY; Tan SH; Tan JJE; Tay DSH; Lee AWX; Ang AJS; Wong LWJ; Choo SP; Tai DW; Lee JJX
    Liver Cancer; 2022 Jan; 11(1):9-21. PubMed ID: 35222504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
    BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
    Inomata M; Matsumoto M; Hayashi K; Seto Z; Hirai T; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Tobe K
    Anticancer Res; 2023 Jul; 43(7):3241-3246. PubMed ID: 37351972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.